Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Driehaus Capital Management

Investor type Private Equity Firm
Founders Richard Driehaus


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 24
Average round size
The average size of a deal this fund participated in
Portfolio companies 22
Rounds per year 0.60
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 11
Key employees 2
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical Device

Driehaus Capital Management is the famous VC, which was founded in 1982. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Chicago.

This Driehaus Capital Management works on 9 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2019. The top amount of exits for fund were in 2019.

We also calculated 2 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Pulmonx, Alloptic. We can highlight the next thriving fund investment areas, such as Marketplace, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The usual cause for the fund is to invest in rounds with 9 partakers. Despite the Driehaus Capital Management, startups are often financed by The Column Group, Remeditex Ventures, Montreux Equity Partners. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, ArrowMark Partners, RTW Investments LLC. In the next rounds fund is usually obtained by GMG Capital Partners, Athenian Venture Partners, Robb Kunz.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Driehaus Capital Management:
Typical Co-investors
Driehaus Capital Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Driehaus Capital Management:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
360 Jinrong China, Shanghai
CBS Corporation New York, New York, United States
Commercial Street Capital Dallas, Texas, United States
Deppon Logistics China, Shanghai
Deutsche Bahn Frankfurt, Germany, Hessen
EM-MEDIA England, Nottingham, United Kingdom
First Image! Ventures -
Forming Circles Global -
Good Company Israel, Tel Aviv, Tel Aviv District
HCL Technologies India, Noida, Uttar Pradesh
Malik Radix Healthcare Delhi, Delhi, India
MTS Ventures Allentown, Pennsylvania, United States
National Center for Advancing Translational Sciences(NCATS) -
OBIC Japan, Tokyo
Playco Japan, Tokyo
signals Venture Capital Berlin, Berlin, Germany
Techno Pacific Assets -
Yongmao Yuanke Gong Mao -
Zubi Labs Spain, Valencia, Valencian Community

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Annexon Biosciences

Health Care
Health Diagnostics
Life Science
$130M08 Jul 2022 South San Francisco, California, United States

Congruence Therapeutics

$50M08 Feb 2022 Montréal, Quebec, Canada

Maze Therapeutics

$190M10 Jan 2022 Redwood City, California, United States

DiCE Molecules

Medical Device
$60M24 Aug 2021 California, United States

Frontier Medicines

Artificial Intelligence
$88M19 Jul 2021 San Francisco, California, United States


Life Science
$135M11 May 2021 Cambridge, Massachusetts, United States


Health Care
Health Diagnostics
$200M05 May 2021 Fort Myers, Florida, United States

C2i Genomics

Health Care
Health Diagnostics
$100M15 Apr 2021 New York, New York, United States

Crinetics Pharmaceuticals

$75M12 Apr 2021 San Diego, California, United States
DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Biotech Company Nuvalent Raises $135 Million

– Nuvalent is a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer.
– The company raised $135m in Series B funding.
Bain Capital Life Sciences led the round and was joined by Deerfield Management, Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Driehaus Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: